RT Journal Article
SR Electronic
T1 Using single molecule Molecular Inversion Probes as a cost-effective, high-throughput sequencing approach to target all genes and loci associated with macular diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.17.22272534
DO 10.1101/2022.03.17.22272534
A1 Rebekkah J. Hitti-Malin
A1 Claire-Marie Dhaenens
A1 Daan M. Panneman
A1 Zelia Corradi
A1 Mubeen Khan
A1 Anneke I. den Hollander
A1 G. Jane Farrar
A1 Christian Gilissen
A1 Alexander Hoischen
A1 Maartje van de Vorst
A1 Femke Bults
A1 Erica G.M. Boonen
A1 Patrick Saunders
A1 MD Study Group
A1 Susanne Roosing
A1 Frans P.M. Cremers
YR 2022
UL http://medrxiv.org/content/early/2022/03/24/2022.03.17.22272534.abstract
AB Background Macular diseases (MDs) are a subgroup of retinal disorders characterized by central vision loss that represent a major cause of vision impairment. Despite the identification of numerous genes associated with inherited MD (iMD) and risk factors associated with age-related MD (AMD), the extent of genetic and non-genetic factors that influence the expression of MD is still not fully explained. Single molecule Molecular Inversion Probes (smMIPs) have proven effective in sequencing the ABCA4 gene in patients with Stargardt disease in a cost-effective manner to identify associated coding and non-coding variation, however a large portion of patients with MDs still remain genetically unexplained.Methods For MD patients, we hypothesized that the missing heritability may be revealed by smMIPs-based sequencing of all MD-associated genes and risk factors. We used 17,394 smMIPs to sequence the coding regions of 105 genes and non-coding or regulatory loci associated with iMD and AMD, known pseudo-exons, and the mitochondrial genome in two test cohorts that had previously been screened for variants in the entire ABCA4 gene.Results Sequencing of 379 probands achieved an average nucleotide coverage of 431× across all targets. Following detailed sequencing analysis of 110 probands, a diagnostic yield of 38% was observed. This established an ‘‘MD-smMIPs panel’’ that allows a genotype-first approach in a high-throughput and cost-effective manner, whilst achieving uniform and high coverage across targets.Conclusions Further analysis will identify known and novel variants in MD-associated genes to offer an accurate clinical diagnosis to patients and their families. Furthermore, this will reveal new genetic associations for MD and potential genetic overlaps between iMD and AMD.Competing Interest StatementAuthor AIdH is currently an employee of AbbVie. Author PS is currently an employee of Molecular Loop BioSciences Inc.Funding StatementThis study was funded by the HRCI HRB Joint Funding Scheme 2020-007, Stichting Oogfonds Nederland (UZ 2020-17), Pro Retina Deutschland, Stichting tot Verbetering van het Lot der Blinden, Stichting voor Ooglijders and the Stichting Blindenhulp.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Prof. Dr. P.N.R. Dekhuijzen on behalf of Commissie Mensgebonden Onderzoek (CMO) of Radboud UMC, Nijmegen gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. All data produced in the present study are available upon reasonable request to the authors.